Table 2.
Some demographic and laboratory data of study subjects.
| Parameter | Controls (n = 150) (mean ± SD) |
Patients (n = 150) (mean ± SD) |
P value |
|---|---|---|---|
| Age (years) | 50.2 ± 4.2 | 52.1 ± 3.8 | 0.223 |
| BMI (kg/m2) | 26.3 ± 3.2 | 27.1 ± 3.5 | 0.275 |
| White blood cell (X103/µl) | 6.7 ± 1.6 | 6.5 ± 1.8 | 0.152 |
| ALT (U/l) | 29.7 ± 3.1 | 31.4 ± 2.9 | 0.417 |
| AST (U/l) | 27.2 ± 7.1 | 28.7 ± 6.8 | 0.599 |
| Albumin (g/l) | 44.0 ± 5.8 | 43.9 ± 6.1 | 0.539 |
| Serum creatinine (μmol/l) | 84.5 ± 11.9 | 85.3 ± 11.1 | 0.397 |
| Blood urea nitrogen (mmol/l) | 6.3 ± 2.0 | 6.8 ± 2.3 | 0.089 |
| PT (s) | 10.7 ± 2.4 | 11.1 ± 2.1 | 0.104 |
| APTT (s) | 31.4 ± 4.5 | 30.1 ± 4.8 | 0.432 |
| Fibrinogen (g/l) | 2.5 ± 1.2 | 3.9 ± 1.6 | 0.000⁎ |
| D-Dimer (ng/ml) | 151.0 ± 81.1 | 549.5 ± 101.2 | 0.007⁎ |
| TAFI Ag (%) | 91.1 ± 19.2 | 101.3 ± 24.4 | 0.004⁎ |
n; number, BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; PT, prothrombin time; APTT, activated partial thromboplastin time; TAFI Ag, thrombin-activatable fibrinolysis inhibitor antigen.
⁎
P < 0.05.